Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.52), $0.30 worse than the analyst estimate of ($1.22). Revenue for the quarter came in at $6.96 million versus the consensus estimate of $19.68 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.